Over the past 25 years, fluctuations in interest rates have foreshadowed major economic crises, with recent patterns showing a similar trajectory since 2022. Historical parallels suggest that the September 2024 rate cut may initiate another crisis, indicating an inevitable decline in stock prices and economic downturn despite market optimism and positive sentiments.
Since making an all-time high on 26 September 2024, the Nifty50 index corrected over the next two weeks. The correction so far has been inconsiderate, with the index giving up just the gains made in September 2024. Meanwhile, the S&P 500 index is at its all-time high, after remaining sluggish and volatile in the previous three … Continue reading Changing Global Economic Trends: What it means for Stock Prices
A Few Companies with Differentiated Business Models led by Innovative and Enterprising Management offer Good Investment Opportunities.
Reviewing the Investment Prospects of Associated Alcohols and Dynemic Products. Conditions become favourable for sustainable earnings growth when a firm with a strong competitive position through productive capital allocation achieves superior operating profitability.
Prospecting for New Opportunities Among Five Stocks. There is no point in being invested in an idea one is not excited about. We are in a stock market boom, all stocks are rising, so the recent better performance of a stock might be reflecting the general euphoria and thus have nothing to do with its fundamentals.
We decided to buy the stock of L G Balakrishnan & Bros (LGBB) when we first discussed the stock in April 2023. Its market price then - ₹745 per share - was at a significant discount to our estimated fair value of ₹1,257 per share. When we reviewed the stock again almost one year later, … Continue reading L G Balakrishnan & Bros: There is Still Value in the Stock
‘HOLD’ was our decision on Lincoln Pharma when we last reviewed the stock in February 2024 as the market price then (₹690 per share) was slightly higher than our estimated fair value. Major headwinds perceived then were the persistently slow pace of earnings growth, sluggish capital allocation, and mediocre working capital management. Now six months … Continue reading Lincoln Pharma: Despite Recent Gains Odds Seem Favourable
Contentment about our investments and money matters is determinant not of what is on the outside but of what happens inside of us. The underlying motivation behind most of our investment endeavours is not just the money but the plethora of opportunities that money opens for us. The bigger house, faster cars, better neighbourhoods, and … Continue reading Finding Contentment in Your Investment Journey
I was positive about Control Print when we last discussed it in February 2024 after its Dec. 2023 quarter results, however, I discouraged buying the stock due to its elevated price. The stock was trading at ₹968 per share then; it now trades at ₹800 per share – down 17.35 per cent in six months. … Continue reading Control Print: Earnings Slowdown a Major Headwind
In the midst of a stock market boom, PPAP Automotive stands out with poor financial performance. Its stock price has stagnated while its competitors have thrived. The company's costs have outpaced revenue growth, leading to declining profitability. Its capital allocation and cash flow are also concerning, indicating a bleak future. It is advisable to avoid investing in this stock.
AMN CAPITAL 